19,595 results match your criteria Myelodysplastic Syndrome


The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q.

Pharmacoecon Open 2018 Dec 14. Epub 2018 Dec 14.

King's College Hospital National Health Service Foundation Trust, London, UK.

Background: Uncertainty within cost-effectiveness analysis, often driven by lack of mature data from large clinical trials, plays a key role in decisions made by the National Institute for Health and Care Excellence (NICE), particularly for early access medicines and orphan drugs.

Objectives: In this case study, we used real-world evidence to address the uncertainty in the cost-effectiveness case for lenalidomide in transfusion-dependent low- and intermediate-1-risk myelodysplastic syndrome (MDS) deletion 5q [del(5q)], affecting a small but unique subpopulation with an orphan disease.

Methods: As part of a submission to NICE, we developed a cost-effectiveness model for lenalidomide, resulting in eventual recommendation. Read More

View Article
December 2018

[Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report].

Rev Med Interne 2018 Dec 11. Epub 2018 Dec 11.

Service d'hématologie-oncologie, CHU Brugmann, 4, place Arthur Van Gehuchten, 1020 Bruxelles, Belgique.

Introduction: Sweet's syndrome is an acute neutrophilic dermatosis characterized by abrupt onset of skin lesions accompanied by fever, arthralgia, leukocytosis and diffuse neutrophilic infiltration of the dermis, as well as an excellent response to corticosteroid therapy.

Case Report: A 46-year-old patient with myelodysplastic syndrome was admitted for chemotherapy. On the eighth day of chemotherapy, he received a single dose of pegfilgrastim. Read More

View Article
December 2018
2 Reads

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.

Br J Haematol 2018 Dec 13. Epub 2018 Dec 13.

Service d'Hématologie Clinique, Hôpital St. Louis and Paris 7 University, Paris, France.

Many patients with lower-risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis-stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly used and recommended by clinical guidelines. To better understand the evidence available on the use of ESAs for anaemia in lower-risk MDS, we conducted a systematic literature review to identify randomized and nonrandomized prospective studies reporting on clinical efficacy/effectiveness, patient-reported quality of life (QoL), and safety. Read More

View Article
December 2018

Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Public Health Sciences, The University of Chicago, Chicago, Illinois.

Background: Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL).

Methods: This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. Read More

View Article
December 2018

Methylation level of Rap1GAP and the clinical significance in MDS.

Oncol Lett 2018 Dec 26;16(6):7287-7294. Epub 2018 Sep 26.

Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, Jiangsu 215006, P.R. China.

Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10-15% patients with MDS. The authors' previous study on the gene expression profile of cluster of differentiation 34 cells using microarray analysis identified elevated expression of RAP1GTPase activating protein 1 (Rap1GAP) in patients with MDS compared with that in non-malignant blood diseases (NM) control group. Read More

View Article
December 2018
2 Reads

Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow.

Haematologica 2018 Dec 13. Epub 2018 Dec 13.

NHLBI/NIH.

Long noncoding RNAs (lncRNAs), which are regulators of cell differentiation and development. The lncRNA transcriptome in human hematopoietic stem and progenitor cells is not comprehensively defined. We investigated lncRNAs in 979 human bone marrow-derived CD34+ cells by single cell RNA sequencing followed by de novo transcriptome reconstruction. Read More

View Article
December 2018

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Haematologica 2018 Dec 13. Epub 2018 Dec 13.

Peter MacCallum Cancer Centre, Melbourne, Australia.

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azacitidine or combination azacitidine (75mg/m2/d days 1 to 5) with lenalidomide (10mg days 1-21 of 28-day cycle from cycle 3) to assess clinical benefit (alive without progressive disease) at 12 months. Read More

View Article
December 2018
2 Reads

How I treat MDS after hypomethylating agent failure.

Authors:
Valeria Santini

Blood 2018 Dec 13. Epub 2018 Dec 13.

MDS Unit, Division of Hematology, AOU Careggi-University of Florence, Florence, Italy, Italy

Hypomethylating agents (HMA), azacitidine and decitabine are standard of care for myelodysplastic syndromes. Response to these agents accounts for around 50% of treated patients and duration of response, although variable, is transient. Prediction of response to HMA is possible with clinical and molecular parameters, but alternative approved treatments are not available and in case of HMA failure, there are no standard therapeutic opportunities. Read More

View Article
December 2018

Trial watch: Peptide-based vaccines in anticancer therapy.

Oncoimmunology 2018 6;7(12):e1511506. Epub 2018 Sep 6.

Université Paris Descartes/Paris V, Paris, France.

Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppression. Several strategies have been developed to overcome such limitations, including the use of immunostimulatory adjuvants, the co-treatment with cytotoxic anticancer therapies that enable the coordinated release of damage-associated molecular patterns, and the concomitant blockade of immune checkpoints. Read More

View Article
September 2018
1 Read

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report.

Case Rep Hematol 2018 4;2018:2525070. Epub 2018 Nov 4.

Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece.

Plasmablastic lymphoma (PBL) is a rare, aggressive type of B-cell non-Hodgkin lymphoma with the vast majority of patients responding poorly to treatment or progressing shortly thereafter. Cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) or CHOP-like regimens have disappointing results in this setting. We report a case of PBL arising in a previously diagnosed myelodysplastic/myeloproliferative (MDS/MPN) with ring sideroblasts and thrombocytopenia (RS-T), HIV-negative patient treated with the combination of CHOP and bortezomib. Read More

View Article
November 2018

Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.

Adv Exp Med Biol 2018 ;995:97-116

Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.

In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical trials are currently ongoing in patients with AML and MDS, both in the frontline and relapsed refractory setting. Read More

View Article
January 2018
4 Reads

GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.

Blood Adv 2018 Dec;2(23):3553-3565

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD.

GATA2 deficiency is an inherited or sporadic genetic disorder characterized by distinct cellular deficiency, bone marrow failure, various infections, lymphedema, pulmonary alveolar proteinosis, and predisposition to myeloid malignancies resulting from heterozygous loss-of-function mutations in the gene. How heterozygous mutations affect human hematopoietic development or cause characteristic cellular deficiency and eventual hypoplastic myelodysplastic syndrome or leukemia is not fully understood. We used induced pluripotent stem cells (iPSCs) to study hematopoietic development in the setting of GATA2 deficiency. Read More

View Article
December 2018

1-2-3 Project: A Quality Improvement Initiative to Normalize and Systematize Palliative Care for All Patients With Cancer in the Outpatient Clinic Setting.

J Oncol Pract 2018 Dec;14(12):e775-e785

Memorial Sloan Kettering Cancer Center, New York, NY.

Background:: Prior work to integrate early palliative care in oncology has focused on patients with advanced cancer and primarily on palliative care consultation. We developed this outpatient clinic initiative for newly diagnosed patients at any stage, emphasizing primary (nonspecialist) palliative care by oncology teams, with enhanced access to palliative care specialists.

Methods:: We piloted the project in two medical oncology specialty clinics (for patients with myelodysplastic syndrome and GI cancer, respectively) to establish feasibility. Read More

View Article
December 2018
1 Read

An in vitro assessment for evaluating the efficiency of β-d-mannuronic acid (M2000) in myelodysplastic syndrome.

J Cell Physiol 2018 Dec 10. Epub 2018 Dec 10.

Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

β-d-Mannuronic acid (M2000), a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties, has been previously shown to exhibit potential therapeutic effects on autoimmune diseases. Immunosuppression therapy has been a standard approach for myelodysplastic syndrome (MDS) for many years. We evaluated the effect of M2000 on isolated peripheral blood mononuclear cells (PBMCs) from patients with MDS. Read More

View Article
December 2018
1 Read
3.839 Impact Factor

A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.

Pediatr Blood Cancer 2018 Dec 11:e27568. Epub 2018 Dec 11.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

Background: Bacillus species are known to cause severe infection in immunocompromised hosts. The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant (HCT) is unknown.

Methods: We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1, 2005, and December 31, 2014, at Boston Children's Hospital. Read More

View Article
December 2018

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.

J Clin Pharmacol 2018 Dec 11. Epub 2018 Dec 11.

Established Products, Janssen Research & Development, Titusville, NJ, USA.

Dacogen, the formulated product of the pharmaceutically active agent decitabine (5 aza-2'-deoxycytidine), is approved for treatment of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). The current analysis was performed to characterize the pharmacokinetics of decitabine in pediatric patients with AML and evaluate their consistency with the PK in adult patients. A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies. Read More

View Article
December 2018

High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome.

Int J Oncol 2018 Dec 4. Epub 2018 Dec 4.

Worldwide Medical Center, Huashan Hospital of Fudan University, Shanghai 200040, P.R. China.

In our previous study, the 4‑aminobutyrate aminotransferase (ABAT) gene was screened and selected as a target gene that may affect the prognosis of myelodysplastic syndrome (MDS). The present study aimed to determine the prognostic value of ABAT in 152 patients with MDS, 29 patients with acute myeloid leukemia (AML) and 40 controls, by detecting the expression and methylation levels of the ABAT gene. In patients with MDS, the expression levels of ABAT were significantly reduced compared with in the controls (P<0. Read More

View Article
December 2018

Cytidine deaminase enables Toll-like receptor 8 activation by cytidine or its analogs.

Int Immunol 2018 Dec 10. Epub 2018 Dec 10.

Division of Innate Immunity, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.

Toll-like receptor 8 (TLR8), a sensor for pathogen-derived single-stranded RNA (ssRNA), binds to uridine (Uri) and ssRNA to induce defense responses. We here show that cytidine (Cyd) with ssRNA also activated TLR8 in peripheral blood leukocytes (PBLs) and a myeloid cell line U937, but not in an embryonic kidney cell line 293T. Cyd deaminase (CDA), an enzyme highly expressed in leukocytes, deaminates Cyd to Uri. Read More

View Article
December 2018
2.536 Impact Factor

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Bone Marrow Transplant 2018 Dec 10. Epub 2018 Dec 10.

The Departments of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Conditioning regimens contribute significantly to outcomes following allogeneic stem cell transplantation (allo-SCT). Reduced-intensity conditioning (RIC) regimens provide lower toxicity at the cost of reduced efficacy compared with myeloablative conditioning (MAC) regimens. However, because pre-transplant prognostic variables often determine the conditioning regimen, studies of RIC vs. Read More

View Article
December 2018

Malignancies in adults living with HIV in Asia.

J Acquir Immune Defic Syndr 2018 Nov 29. Epub 2018 Nov 29.

Taipei Veterans General Hospital, Taipei, Taiwan.

BackgroundHaematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence, risk factors for, and outcomes of haematological and non-haematological malignancies in PLHIV in Asia.MethodsIncidence of malignancy after cohort enrolment was evaluated. Read More

View Article
November 2018
1 Read
4.556 Impact Factor

[Association between SAMD9/SAMD9L and hematological malignancies].

Rinsho Ketsueki 2018 ;59(11):2475-2480

Department of Pediatrics, Keio University School of Medicine.

In this article, knowledge about SAMD9/SAMD9L molecules, which has been a topic of interest in the field of hematological malignancies, was reviewed. Based on clinical genetic research on hematologic malignancies with chromosome 7 abnormality (e.g. Read More

View Article
January 2018

[Pure red cell aplasia following the rapid reduction and discontinuation of cyclosporine for mixed chimerism after allogeneic bone marrow transplantation].

Rinsho Ketsueki 2018 ;59(11):2408-2412

Department of Pediatrics, Kyoto Prefectural University of Medicine.

A 19-year-old male with therapy-related myelodysplastic syndrome underwent allogeneic bone marrow transplantation with reduced-intensity conditioning from his HLA-identical sibling whose ABO blood type exhibited major incompatibility with the patient. After post-transplantation 1 month, chimerism analysis of the bone marrow revealed mixed chimerism with 30% of recipient cells, and after post-transplantation 3 months, complete remission was maintained; however, recipient granulocytes were elevated up to 50% per the chimerism analysis. Next, pancytopenia developed following the rapid discontinuation of the immunosuppressive agent. Read More

View Article
January 2018

Analysis of clinical and molecular features of MDS patients with complex karyotype in China.

Blood Cells Mol Dis 2018 Nov 22;75:13-19. Epub 2018 Nov 22.

Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China. Electronic address:

We retrospectively analyzed 101 primary MDS patients with complex karyotype during January 2010 and April 2017.The median overall survival (OS) time was 13 (95% CI 9.98-16. Read More

View Article
November 2018

Myelodysplastic syndromes and acute myeloid leukemias in the elderly.

Eur J Intern Med 2018 Dec;58:28-32

Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland. Electronic address:

Most patients above 60 years with acute myeloid leukemia (AML) will die from their disease. Nevertheless, the treatment concepts in elderly patients with myelodysplastic syndromes (MDS) and AML are rapidly evolving. A number of recent reports have identified better survival rates with intensive induction chemotherapy for patients up to 80 years, with the exception of patients with unfavorable genomic risk abnormalities or with major co-morbidities. Read More

View Article
December 2018

Unexplained cytopenias in an adolescent? You GATA think about it.

J Assoc Genet Technol 2018 ;44(4):135-136

Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT.

Objectives: The GATA family of DNA binding proteins consists of six different transcription factors (GATA1-6), each with a diverse biologic function. The transcription factors GATA1-3 function primarily to orchestrate hematopoiesis; however, they have roles in non-hematopoietic cells as well. Much of our current knowledge of the GATA transcription factors has come through observation of disease states with known GATA mutations. Read More

View Article
January 2018
2 Reads

Benzene Exposure Response and Risk of Myeloid Neoplasms in Chinese Workers: A Multicenter Case-Cohort Study.

J Natl Cancer Inst 2018 Dec 6. Epub 2018 Dec 6.

Nanchang Center for Disease Control and Prevention, Nanchang, China.

Background: There is international consensus that benzene exposure is causally related to acute myeloid leukemia (AML), and more recent evidence of association with myelodysplastic syndromes (MDS). However, there are uncertainties about the exposure response, particularly risks by time since exposure and age at exposure.

Methods: In a case-cohort study in 110 631 Chinese workers followed up during 1972-1999 we evaluated combined MDS/AML (n = 44) and chronic myeloid leukemia (n = 18). Read More

View Article
December 2018
5 Reads

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.

Adv Hematol 2018 1;2018:2458679. Epub 2018 Nov 1.

Medical University of Varna, Varna, Bulgaria.

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Read More

View Article
November 2018
2 Reads

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Blood Adv 2018 Dec;2(23):3447-3461

Department of Medicine III, Technische Universität München, Munich, Germany.

Mesenchymal stromal cells (MSCs) are crucial components of the bone marrow (BM) microenvironment essential for regulating self-renewal, survival, and differentiation of hematopoietic stem/progenitor cells (HSPCs) in the stem cell niche. MSCs are functionally altered in myelodysplastic syndromes (MDS) and exhibit an altered methylome compared with MSCs from healthy controls, thus contributing to disease progression. To determine whether MSCs are amenable to epigenetic therapy and if this affects their function, we examined growth, differentiation, and HSPC-supporting capacity of ex vivo-expanded MSCs from MDS patients in comparison with age-matched healthy controls after direct treatment in vitro with the hypomethylating agent azacitidine (AZA). Read More

View Article
December 2018
2 Reads

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a median follow-up of 15·4 months (IQR 13·7-17·3), 89 (82%) of 108 assessable patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel achieved an objective response, and complete responses were noted in 63 (58%) patients. Here we report long-term activity and safety outcomes of the ZUMA-1 study. Read More

View Article
November 2018
1 Read
24.690 Impact Factor

A brief, but comprehensive, guide to clonal evolution in aplastic anemia.

Authors:
Daria V Babushok

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):457-466

Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; and.

Acquired aplastic anemia (AA) is an immune-mediated bone marrow aplasia that is strongly associated with clonal hematopoiesis upon marrow recovery. More than 70% of AA patients develop somatic mutations in their hematopoietic cells. In contrast to other conditions linked to clonal hematopoiesis, such as myelodysplastic syndrome (MDS) or clonal hematopoiesis of indeterminate potential in the elderly, the top alterations in AA are closely related to its immune pathogenesis. Read More

View Article
November 2018
5 Reads

Treatments targeting MDS genetics: a fool's errand?

Authors:
Amy E DeZern

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):277-285

Division of Hematologic Malignancies, John Hopkins Medicine, Baltimore, MD.

The myelodysplastic syndromes are collectively the most common myeloid neoplasms. Clonal hematopoiesis present in these diseases results in bone marrow failure characteristically seen in patients. The heterogeneity of myelodysplastic syndrome pathobiology has historically posed a challenge to the development of newer therapies. Read More

View Article
November 2018
1 Read

The MDS genomics-prognosis symbiosis.

Authors:
Aziz Nazha

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):270-276

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Myelodysplastic syndromes (MDS) are clonal disorders characterized by the accumulation of complex genomic abnormalities that define disease phenotype, prognosis, and the risk of transformation to acute myeloid leukemia. The clinical manifestations and overall outcomes of MDS are very heterogeneous with an overall survival that can be measured in years for some patients to a few months for others. Prognostic scoring systems are important staging tools that aid physicians in their treatment recommendations and decision-making and can help patients understand their disease trajectory and expectations. Read More

View Article
November 2018
1 Read

Successful treatment of invasive pulmonary aspergillosis caused by Aspergillus felis, a cryptic species within the Aspergillus section Fumigati: A case report.

J Infect Chemother 2018 Nov 30. Epub 2018 Nov 30.

Department of Infection Control Science, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan; Research Center for Infectious Disease Sciences (RCIDS), Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. Electronic address:

Aspergillus species are a major cause of life-threatening infections in immunocompromised hosts, and the most common pathogen of invasive aspergillosis is Aspergillus fumigatus. Recently, the development of molecular identification has revealed cryptic Aspergillus species, and A. felis is one such species within the Aspergillus section Fumigati reported in 2013. Read More

View Article
November 2018
1 Read

Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.

Semin Hematol 2018 Oct 28;55(4):242-247. Epub 2018 May 28.

Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department for BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address:

Myelodysplastic syndromes (MDS) and associated diseases, like chronic myelomonocytic leukemias (CMML), are heterogeneous, clonal disorders affecting the hematopoietic stem cells. They are characterized by dysplasia and a propensity to evolve toward acute myeloid leukemia. Systemic inflammatory and autoimmune manifestations (SIAMs) occur with a prevalence of 10% to 20% in myeloid malignancies, but the underlying pathogenetic mechanisms remain obscure. Read More

View Article
October 2018
1 Read

Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.

Semin Hematol 2018 Oct 21;55(4):202-208. Epub 2018 Feb 21.

Hematology department, Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.

Azacitidine (AZA) treatment is effective treatment for patients with myeloid disorders, and factors predictive of treatment outcome are under investigation. Little is known about the effect of bone marrow fibrosis on response to AZA therapy. We, retrospectively, evaluated clinical predictors of overall survival (OS) and overall response rate (ORR) for patients treated with AZA in a real-life cohort. Read More

View Article
October 2018
1 Read

[Effects of Abnormal Iron Metabolism on EPO-STAT5 Signaling Pathway in Anemia Patients].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1726-1730

Department of Hematology, East Hospital of The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 201306,

Objective: To study the effects of iron metabolism abnormality on EPO-STAT5 signaling pathway in anemia patients.

Methods: According to diseases, the patients were divided into 3 groups: lower risk myelodysplastic syndrome (MDS) group (30 cases) including 14 cases of non-iron over load and 16 cases of iron over load, 12 cases of them were treated by iron chelation therapy; anemia of chronic disease (ACD) group (12 cases) and iron deficiency anemia (IDA) group (12 cases). In addition, the healthy control group was selected. Read More

View Article
December 2018
1 Read

[Predicting Therapeutic Response by Lymphocyte Level at 28th Day after DAC Treatment in Patients with MDS].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1719-1725

Department of Hematology, The Afilliatied Hospital of Hebei Universtity,Baoding 071000, Hebei Province, China.E-mail:

Objective: To investigate a reliable clinical indication for predicting the therapeutic response of decitabine therapy in the patients with myelodysplastic syndromes (MDS).

Methods: The clinical efficacy of decitabine for 55 cases of MDS was analyzed retrospectively. According to the lymphocyte level at d28 after the first time treatment with decitabine, the patients were divided into high lymphocyte level group (H-Lym≥1. Read More

View Article
December 2018
1 Read

[Correlation of the Serum bFGF Level with MDS Typing, Serum IL-32 Level and Prognosis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1708-1712

Department of Hematology, The Fourth Hospital of Wuhan, Wuhan 430030, Hubei Province, China.E-mail:

Objective: To investigate the correlation of serum bFGF level with MDS typing, serum IL-32 and prognosis.

Methods: A total of 62 patients with myelodysplastic syndromes admitted in our hospital from April of 2014 to April of 2017 were enrolled in MDS group. And 50 healthy people who received healthy physical examination in our hospital were selected as the control group at the same period. Read More

View Article
December 2018
1 Read

[Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1702-1707

Department of Hematology, Haiyang Municipal People's Hospital, Haiyang 265100, Shandong Province, China.

Objective: To explore the clinical efficacy of decitabine for treatment of patients with myelodysplastic syndrome (MDS) and factors predicting the prognosis.

Methods: The clinical data of 87 patients with MDS treated with decitabine were analyzed retrospectively. The hENT1 mRNA expression and TP53 gene mutation were detected by Q-PCR and gene target sequencing, respectively. Read More

View Article
December 2018
2 Reads

[Clinical Charcteristics and Prognostic Analysis of 28 cases of Pediatric Myelodysplastic Syndrome].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1695-1701

Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China.E-mail:

Objective: To analyze the clinical features and prognosis of 28 children with myelodysplastic syndrome (MDS) and to screen the high risk factors affecting the prognosis so as to provide the new ideas for standard of clinical diagnosis and therapy.

Methods: The clinical data of 28 children with newly diagnosed MDS treated in our hospital from March 1994 to July 2016 were analyzed retrospectively, the features of disease onset and the results of laboratory examination were summarized, all MDS children were followed up, the prognosis and the high risk factors affecting the prognosis were evaluated.

Results: In all 28 MDS children, the ratio of male to female was 1. Read More

View Article
December 2018
1 Read

Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Int J Hematol 2018 Dec 5. Epub 2018 Dec 5.

Division of Cellular Therapy, Advanced Clinical Research Center, Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 1088639, Japan.

An epigenetic modulator Additional sex combs-like 1 (ASXL1) is recurrently mutated in myeloid neoplasms such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs). ASXL1 mutations are also frequently detected in clonal hematopoiesis with indeterminate potential (CHIP), which is the clonal expansion of premalignant hematopoietic cells without any evidence of hematological malignancies. Thus, understanding the roles of ASXL1 in hematopoiesis and myeloid neoplasms is a clinically crucial issue. Read More

View Article
December 2018
1 Read

Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.

Nat Med 2018 Dec 3. Epub 2018 Dec 3.

Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.

Myelodysplastic syndromes (MDS) frequently progress to acute myeloid leukemia (AML); however, the cells leading to malignant transformation have not been directly elucidated. As progression of MDS to AML in humans provides a biological system to determine the cellular origins and mechanisms of neoplastic transformation, we studied highly fractionated stem cell populations in longitudinal samples of patients with MDS who progressed to AML. Targeted deep sequencing combined with single-cell sequencing of sorted cell populations revealed that stem cells at the MDS stage, including immunophenotypically and functionally defined pre-MDS stem cells (pre-MDS-SC), had a significantly higher subclonal complexity compared to blast cells and contained a large number of aging-related variants. Read More

View Article
December 2018
1 Read

Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.

Leuk Lymphoma 2018 Nov 30:1-6. Epub 2018 Nov 30.

a Department of Hematology , University Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB) , Spain.

In clinical practice, patients with myelodysplastic syndromes (MDS) are usually classified in low or high-risk groups to take therapeutic decisions, conservative for low-risk, whereas active for high-risk. Nevertheless, in the Revised International Prognostic Scoring System (IPSS-R) is not well stated which patients are low or high-risk. This study was aimed to ascertain in 364 MDS patients which IPSS-R threshold better dichotomized in low vs. Read More

View Article
November 2018
3 Reads

Pseudogout: An Autoimmune Paraneoplastic Manifestation of Myelodysplastic Syndrome.

Cureus 2018 Sep 27;10(9):e3372. Epub 2018 Sep 27.

Internal Medicine, University at Buffalo / Sisters of Charity Hospital, Buffalo, USA.

Myelodysplastic syndrome (MDS) is often associated with autoimmune paraneoplastic manifestations. Seronegative arthritis is among one of them. Very rarely, pseudogout demonstrated as paraneoplastic autoimmune manifestations of MDS has been adumbrated so far. Read More

View Article
September 2018
4 Reads

An isolated der(1;21)(q10;q10) translocation in a patient with myelodysplastic syndrome: a case report.

Am J Blood Res 2018 5;8(3):17-20. Epub 2018 Oct 5.

Osaka General Hospital of West Japan Railway Company 1-2-22 Matsuzaki-cho, Abeno-ku, Osaka 545-0053, Japan.

Whole-arm translocations are relatively rare among hematological malignancies. There are a few reports on myeloid malignancies harboring der(1;21)(q10;q10). A 65-year-old male was referred to our hospital due to squamous cell carcinoma of the lung. Read More

View Article
October 2018
1 Read

Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.

J Cell Mol Med 2018 Nov 28. Epub 2018 Nov 28.

Hematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil.

The role of tumour microenvironment in neoplasm initiation and malignant evolution has been increasingly recognized. However, the bone marrow mesenchymal stromal cell (BMMSC) contribution to disease progression remains poorly explored. We previously reported that the expression of serine protease inhibitor kunitz-type2 (SPINT2/HAI-2), an inhibitor of hepatocyte growth factor (HGF) activation, is significantly lower in BMMSC from myelodysplastic syndromes (MDS) patients compared to healthy donors (HD). Read More

View Article
November 2018
1 Read

Retrospective evaluation of bone marrow cell morphology in a cohort of patients with isolated idic(20q-) karyotypic abnormalities.

Ann Hematol 2018 Nov 27. Epub 2018 Nov 27.

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Street, Suzhou, 215006, Jiangsu, People's Republic of China.

Isochromosome 20q- (i(20q-)), as a rare reproducible chromosomal anomaly formed on the basis of 20q-, has not been commonly reported. Due to the rarity of this karyotypic anomaly, the bone marrow morphological characteristics of the patients with i(20q-) have not been clarified until now. In this study, the bone marrow cell morphology from MDS patients with isolated i(20q-), isolated 20q-, and normal karyotype was retrospectively compared and statistically analyzed. Read More

View Article
November 2018
1 Read

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.

Front Pharmacol 2018 13;9:1279. Epub 2018 Nov 13.

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

Cutaneous manifestations in hematologic malignancies, especially in leukemia, are not common and may be very variable. Here we report a very unusual case of a patient (female, 70 years old) who was admitted to the hospital in 2016 because of skin lesions on the face, the trunk of the body and the extremities. She had a history of breast cancer in the year 2004 (pT1b, pN0, cM0, L0, V0, R0) which had been resected and treated with adjuvant radiation and chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracile) as well as psoriasis treated with methotrexate and cyclosporine. Read More

View Article
November 2018
2 Reads